A narrative review on tofacitinib : The properties, function, and usefulness to treat coronavirus disease 2019
Copyright: © 2023 International Journal of Critical Illness and Injury Science..
In coronavirus disease 2019 (COVID-19), the formation of cytokine storm may have a role in worsening of the disease. By attaching the cytokines like interleukin-6 to the cytokine receptors on a cell surface, Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway will be activated in the cytoplasm lead to hyperinflammatory conditions and acute respiratory distress syndrome. Inhibition of JAK/STAT pathway may be useful to prevent the formation of cytokine storm. Tofacitinib is a pan inhibitor of JAKs. In this review, the main characteristics of tofacitinib and its usefulness against COVID-19 pneumonia were reviewed. Tofacitinib may be a hopeful therapeutic candidate against COVID-19 respiratory injury since it inhibits a range of inflammatory pathways. Hence, the agent may be considered a potential therapeutic against the post-COVID-19 respiratory damage. Compared to other JAK inhibitors (JAKi), the administration of tofacitinib in COVID-19 patients may be safer and more effective. Other JAKi such as baricitinib are related to severe adverse events such as thrombotic events compared to more common side effects of tofacitinib.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
International journal of critical illness and injury science - 13(2023), 4 vom: 03. Okt., Seite 192-198 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hashemian, Seyed Mohammad Reza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coronavirus disease 2019 |
|---|
| Anmerkungen: |
Date Revised 01.02.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4103/ijciis.ijciis_27_23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36782714X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36782714X | ||
| 003 | DE-627 | ||
| 005 | 20240201232252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240131s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/ijciis.ijciis_27_23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1277.xml |
| 035 | |a (DE-627)NLM36782714X | ||
| 035 | |a (NLM)38292399 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hashemian, Seyed Mohammad Reza |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A narrative review on tofacitinib |b The properties, function, and usefulness to treat coronavirus disease 2019 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2023 International Journal of Critical Illness and Injury Science. | ||
| 520 | |a In coronavirus disease 2019 (COVID-19), the formation of cytokine storm may have a role in worsening of the disease. By attaching the cytokines like interleukin-6 to the cytokine receptors on a cell surface, Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway will be activated in the cytoplasm lead to hyperinflammatory conditions and acute respiratory distress syndrome. Inhibition of JAK/STAT pathway may be useful to prevent the formation of cytokine storm. Tofacitinib is a pan inhibitor of JAKs. In this review, the main characteristics of tofacitinib and its usefulness against COVID-19 pneumonia were reviewed. Tofacitinib may be a hopeful therapeutic candidate against COVID-19 respiratory injury since it inhibits a range of inflammatory pathways. Hence, the agent may be considered a potential therapeutic against the post-COVID-19 respiratory damage. Compared to other JAK inhibitors (JAKi), the administration of tofacitinib in COVID-19 patients may be safer and more effective. Other JAKi such as baricitinib are related to severe adverse events such as thrombotic events compared to more common side effects of tofacitinib | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Coronavirus disease 2019 | |
| 650 | 4 | |a Janus kinase inhibitors | |
| 650 | 4 | |a pneumonia | |
| 650 | 4 | |a syndrome coronavirus 2 | |
| 650 | 4 | |a tofacitinib | |
| 700 | 1 | |a Farhadi, Tayebeh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of critical illness and injury science |d 2012 |g 13(2023), 4 vom: 03. Okt., Seite 192-198 |w (DE-627)NLM218049730 |x 2229-5151 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:4 |g day:03 |g month:10 |g pages:192-198 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/ijciis.ijciis_27_23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 4 |b 03 |c 10 |h 192-198 | ||